Bernardo Bonanni

No ORCID on file · 3 papers in corpus
other 2017
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Nature genetics ·doi:10.1038/ng.3826

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptib…

review 2016
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as wit…

rct 2013
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
Breast cancer research : BCR ·doi:10.1186/bcr3439

INTRODUCTION: We previously demonstrated that 1 or 5 mg per day of tamoxifen (T) given for four weeks before surgery reduces Ki-67 in breast cancer (BC) patients to the same extent as the standard 20 mg/d. Given the long half-life of T, a w…